Study: Gene variant affects response to bowel cancer drugs

10/23/2008 | Bloomberg · Yahoo!

Advanced colon cancer patients with a mutation in the BRAF gene do not respond to ImClone Systems' Erbitux and Amgen's Vectibix, Italian researchers reported. The finding comes after earlier studies showed that another gene called KRAS can help identify patients who are most likely to benefit from both drugs.

View Full Article in:

Bloomberg · Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC